EP Patent

EP3534947A1 — Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Assigned to Kymab Ltd · Expires 2019-09-11 · 7y expired

What this patent protects

The present invention relates to combinations comprising anti-human OX40L antibodies, new biomarkers of autoimmune or alloimmune diseases, and their use in various therapeutic methods.

USPTO Abstract

The present invention relates to combinations comprising anti-human OX40L antibodies, new biomarkers of autoimmune or alloimmune diseases, and their use in various therapeutic methods.

Drugs covered by this patent

Patent Metadata

Patent number
EP3534947A1
Jurisdiction
EP
Classification
—
Expires
2019-09-11
Drug substance claim
No
Drug product claim
No
Assignee
Kymab Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.